1-20 of 47
Timothy A. Yap
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Correction: AT13148 Is a Novel, Oral Multi-AGC Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity

Free
Timothy A. Yap, Mike I. Walton, Kyla M. Grimshaw, Robert H. te Poele, Paul D. Eve, Melanie R. Valenti, Alexis K. de Haven Brandon, Vanessa Martins, Anna Zetterlund, Simon P. Heaton, Kathrin Heinzmann, Paul S. Jones, Ruth E. Feltell, Matthias Reule, Steven J. Woodhead, Thomas G. Davies, John F. Lyons, Florence I. Raynaud, Suzanne A. Eccles, Paul Workman, Neil T. Thompson, Michelle D. Garrett
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (13): 2840.
https://doi.org/10.1158/1078-0432.CCR-25-1021
Published: 01 July 2025
View articletitled, Correction: AT13148 Is a Novel, Oral Multi-AGC Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity
Open the PDF for Correction: AT13148 Is a Novel, Oral Multi-AGC Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity in another window
Includes: Supplementary data
Journal Articles

Abstract P1-01-27: HER2 Loss Following Treatment with Trastuzumab Deruxtecan in Patients with Metastatic Breast Cancer

Free
Mohamed Gouda, Amrit Gonugunta, Ecaterina Dumbrava, Timothy A Yap, Jordi Rodon, Sarina A Piha-Paul, Paula R. Pohlmann, Senthil Damodaran, Rashmi Murthy, Vicente Valero, Jason Mouabbi, Debasish Tripathy, Aysegul Sahin, Hui Chen, Funda Meric-Bernstam
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (12_Supplement): P1-01-27.
https://doi.org/10.1158/1557-3265.SABCS24-P1-01-27
Published: 13 June 2025
View articletitled, Abstract P1-01-27: HER2 Loss Following Treatment with Trastuzumab Deruxtecan in Patients with Metastatic Breast Cancer
Journal Articles

Abstract P5-07-28: The next-generation CDK4-selective inhibitor atirmociclib (PF-07220060) in combination with letrozole as first-line treatment in patients with HR+/HER2+ metastatic breast cancer

Free
Antonio Giordana, Manuel Magallanes, Binghe Xu, Diego Kaen, Ernesto Korbenfeld, Min Yan, Omar Zayas Villanueva, Carlos Alberto Hernandez, Peter Schmid, Michal Mego, Santiago Bella, Xinhong WU, Feng Liu, Cynthia Basu, Jennifer Park, Heather Neumann, Maria Delioukina, Timothy A. Yap
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (12_Supplement): P5-07-28.
https://doi.org/10.1158/1557-3265.SABCS24-P5-07-28
Published: 13 June 2025
View articletitled, Abstract P5-07-28: The next-generation CDK4-selective inhibitor atirmociclib (PF-07220060) in combination with letrozole as first-line treatment in patients with HR+/HER2+ metastatic breast cancer
Journal Articles

First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer

Open Access
Timothy A. Yap, Jonathan W. Goldman, Shaveta Vinayak, Antoaneta Tomova, Erika Hamilton, Yoichi Naito, Antonio Giordano, Igor Bondarenko, Toshinari Yamashita, Li Zhou, Allison Moreau, Heather Neumann, Jessica Tougias, Feng Liu, Jennifer Park, Maria Delioukina, Komal Jhaveri
Journal: Clinical Cancer Research
Clin Cancer Res OF1–OF11.
https://doi.org/10.1158/1078-0432.CCR-24-2740
Published: 20 May 2025
View articletitled, First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer
Open the PDF for First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Human Epidermal Growth Factor Receptor 2 Loss following Treatment with Trastuzumab Deruxtecan in Patients with Metastatic Breast Cancer

Available to Purchase
Mohamed A. Gouda, Amrit Gonugunta, Ecaterina E. Dumbrava, Timothy A. Yap, Jordi Rodon, Sarina A. Piha-Paul, Paula R. Pohlmann, Senthil Damodaran, Rashmi Murthy, Vicente Valero, Jason A. Mouabbi, Debasish Tripathy, Aysegul A. Sahin, Hui Chen, Funda Meric-Bernstam
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (7): 1268–1274.
https://doi.org/10.1158/1078-0432.CCR-24-3468
Published: 01 April 2025
View articletitled, Human Epidermal Growth Factor Receptor 2 Loss following Treatment with Trastuzumab Deruxtecan in Patients with Metastatic Breast Cancer
Open the PDF for Human Epidermal Growth Factor Receptor 2 Loss following Treatment with Trastuzumab Deruxtecan in Patients with Metastatic Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Intratumoral or Subcutaneous MK-2118, a Noncyclic Dinucleotide STING Agonist, with or without Pembrolizumab, for Advanced or Metastatic Solid Tumors or Lymphomas

Open Access
Jason J. Luke, Randy F. Sweis, J. Randolph Hecht, Reva Schneider, Mark N. Stein, Talia Golan, Timothy A. Yap, Anuradha Khilnani, Mo Huang, Runchen Zhao, Thomas Jemielita, Sandip Pravin Patel
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (7): 1233–1242.
https://doi.org/10.1158/1078-0432.CCR-24-2824
Published: 01 April 2025
View articletitled, Intratumoral or Subcutaneous MK-2118, a Noncyclic Dinucleotide STING Agonist, with or without Pembrolizumab, for Advanced or Metastatic Solid Tumors or Lymphomas
Open the PDF for Intratumoral or Subcutaneous MK-2118, a Noncyclic Dinucleotide STING Agonist, with or without Pembrolizumab, for Advanced or Metastatic Solid Tumors or Lymphomas in another window
Includes: Supplementary data
Journal Articles

Abstract A005: 18F-Fluorthanatrace PARP inhibitor PET tracer: Potential implications for theranostics

Free
Lilie Lin, Mahmoud Hammad, Franklin Wong, Timothy A. Yap
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (2_Supplement): A005.
https://doi.org/10.1158/1557-3265.TARGETEDTHERAP-A005
Published: 26 January 2025
View articletitled, Abstract A005: 18F-Fluorthanatrace PARP inhibitor PET tracer: Potential implications for theranostics
Journal Articles

Utilizing Patient-Derived Xenografts to Model Precision Oncology for Biliary Tract Cancer

Open Access
Timothy P. DiPeri, Kurt W. Evans, Stephen Scott, Xiaofeng Zheng, Kaushik Varadarajan, Lawrence N. Kwong, Michael Kahle, Hop S. Tran Cao, Ching-Wei Tzeng, Thuy Vu, Sunhee Kim, Fei Su, Maria Gabriela Raso, Yasmeen Rizvi, Ming Zhao, Huamin Wang, Sunyoung S. Lee, Timothy A. Yap, Jordi Rodon, Milind Javle, Funda Meric-Bernstam
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (2): 387–402.
https://doi.org/10.1158/1078-0432.CCR-24-1233
Published: 17 January 2025
View articletitled, Utilizing Patient-Derived Xenografts to Model Precision Oncology for Biliary Tract Cancer
Open the PDF for Utilizing Patient-Derived Xenografts to Model Precision Oncology for Biliary Tract Cancer in another window
Includes: Supplementary data
Journal Articles

First-in-Human Dose-Escalation Study of the First-in-Class PDE3A–SLFN12 Complex Inducer BAY 2666605 in Patients with Advanced Solid Tumors Coexpressing SLFN12 and PDE3A

Open Access
Kyriakos P. Papadopoulos, Meredith McKean, Silvia Goldoni, Isabelle Genvresse, Marine F. Garrido, Rui Li, Gary Wilkinson, Christoph Kneip, Timothy A. Yap
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (24): 5568–5576.
https://doi.org/10.1158/1078-0432.CCR-24-2713
Published: 16 December 2024
View articletitled, First-in-Human Dose-Escalation Study of the First-in-Class PDE3A–SLFN12 Complex Inducer BAY 2666605 in Patients with Advanced Solid Tumors Coexpressing SLFN12 and PDE3A
Open the PDF for First-in-Human Dose-Escalation Study of the First-in-Class PDE3A–SLFN12 Complex Inducer BAY 2666605 in Patients with Advanced Solid Tumors Coexpressing SLFN12 and PDE3A in another window
Includes: Supplementary data
Journal Articles

First-in-Human Dose-Escalation Study of Fianlimab, an Antilymphocyte Activation Gene-3 Antibody, with Cemiplimab in Patients with Advanced Malignancies

Open Access
Nehal J. Lakhani, Kyriakos P. Papadopoulos, Melissa Lynne Johnson, Haeseong Park, Ding Wang, Timothy A. Yap, Afshin Dowlati, Robert G. Maki, Susanna Ulahannan, Filipa Lynce, Karen Kelly, Stephen Williamson, Jyoti Malhotra, Shuquan Chen, Ana Gonzalez Ortiz, Vladimir Jankovic, Anne Paccaly, Sheila Masinde, Jayakumar Mani, Israel Lowy, Giuseppe Gullo, Tasha Sims, Glenn Kroog
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (24): 5601–5611.
https://doi.org/10.1158/1078-0432.CCR-23-3883
Published: 16 December 2024
View articletitled, First-in-Human Dose-Escalation Study of Fianlimab, an Antilymphocyte Activation Gene-3 Antibody, with Cemiplimab in Patients with Advanced Malignancies
Open the PDF for First-in-Human Dose-Escalation Study of Fianlimab, an Antilymphocyte Activation Gene-3 Antibody, with Cemiplimab in Patients with Advanced Malignancies in another window
Includes: Supplementary data
Journal Articles

Oncology Combination Drug Development Strategies for Project Optimus

Available to Purchase
Timothy A. Yap, Julie Bullock, Susan Chong, Megan K. Doyle, Azher Hussain, Jackie Kline, Amandine Manon, Karthik Venkatakrishnan, Vijay V. Upreti
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (23): 5237–5241.
https://doi.org/10.1158/1078-0432.CCR-24-1836
Published: 02 December 2024
View articletitled, Oncology Combination Drug Development Strategies for Project Optimus
Open the PDF for Oncology Combination Drug Development Strategies for Project Optimus in another window
Journal Articles

PIKing up and AKTing on Resistance Mutations in Osimertinib-Treated EGFR-Mutated NSCLC

Available to Purchase
Natalie I. Vokes, Xiuning Le, Timothy A. Yap
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (18): 3968–3970.
https://doi.org/10.1158/1078-0432.CCR-24-1188
Published: 13 September 2024
View articletitled, PIKing up and AKTing on Resistance Mutations in Osimertinib-Treated EGFR-Mutated NSCLC
Open the PDF for PIKing up and AKTing on Resistance Mutations in Osimertinib-Treated EGFR-Mutated NSCLC in another window
Journal Articles

First-in-Human Study of the Ataxia Telangiectasia and Rad3-Related (ATR) Inhibitor Tuvusertib (M1774) as Monotherapy in Patients with Solid Tumors

Open Access
Timothy A. Yap, Anthony W. Tolcher, Ruth Plummer, Jatinder Kaur Mukker, Marta Enderlin, Christine Hicking, Thomas Grombacher, Giuseppe Locatelli, Zoltan Szucs, Ioannis Gounaris, Johann S. de Bono
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (10): 2057–2067.
https://doi.org/10.1158/1078-0432.CCR-23-2409
Published: 15 May 2024
View articletitled, First-in-Human Study of the Ataxia Telangiectasia and Rad3-Related (ATR) Inhibitor Tuvusertib (M1774) as Monotherapy in Patients with Solid Tumors
Open the PDF for First-in-Human Study of the Ataxia Telangiectasia and Rad3-Related (ATR) Inhibitor Tuvusertib (M1774) as Monotherapy in Patients with Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Ataxia-Telangiectasia Mutated Loss-of-Function Displays Variant and Tissue-Specific Differences across Tumor Types

Open Access
Patrick G. Pilié, Virginia Giuliani, Wei-Lien Wang, Daniel J. McGrail, Christopher A. Bristow, Natalie Y.L. Ngoi, Keith Kyewalabye, Khalida M. Wani, Hung Le, Erick Campbell, Nora S. Sanchez, Dong Yang, Jinesh S. Gheeya, Rohit Vivek Goswamy, Vijaykumar Holla, Kenna Rael Shaw, Funda Meric-Bernstam, Chiu-Yi Liu, XiaoYan Ma, Ningping Feng, Annette A. Machado, Jennifer P. Bardenhagen, Christopher P. Vellano, Joseph R. Marszalek, Eeson Rajendra, Desiree Piscitello, Timothy I. Johnson, Maria Likhatcheva, Elias Elinati, Jayesh Majithiya, Joana Neves, Vera Grinkevich, Marco Ranzani, Marina Roy Luzarraga, Marie Boursier, Lucy Armstrong, Lerin Geo, Giorgia Lillo, Wai Yiu Tse, Alexander J. Lazar, Scott E. Kopetz, Mary K. Geck Do, Sarah Lively, Michael G. Johnson, Helen M.R. Robinson, Graeme C.M. Smith, Christopher L. Carroll, M. Emilia Di Francesco, Philip Jones, Timothy P. Heffernan, Timothy A. Yap
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (10): 2121–2139.
https://doi.org/10.1158/1078-0432.CCR-23-1763
Published: 15 May 2024
View articletitled, Ataxia-Telangiectasia Mutated Loss-of-Function Displays Variant and Tissue-Specific Differences across Tumor Types
Open the PDF for Ataxia-Telangiectasia Mutated Loss-of-Function Displays Variant and Tissue-Specific Differences across Tumor Types in another window
Includes: Supplementary data
Journal Articles

Development of a Practical Nomogram for Personalized Anemia Management in Patients Treated with Ataxia Telangiectasia and Rad3-related Inhibitor Camonsertib

Open Access
Ezra Rosen, Timothy A. Yap, Elizabeth K. Lee, Martin Højgaard, Niharika B. Mettu, Stephanie Lheureux, Benedito A. Carneiro, Ruth Plummer, Adrian J. Fretland, Danielle Ulanet, Yi Xu, Robin McDougall, Maria Koehler, Elisa Fontana
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (4): 687–694.
https://doi.org/10.1158/1078-0432.CCR-23-2080
Published: 16 February 2024
View articletitled, Development of a Practical Nomogram for Personalized Anemia Management in Patients Treated with Ataxia Telangiectasia and Rad3-related Inhibitor Camonsertib
Open the PDF for Development of a Practical Nomogram for Personalized Anemia Management in Patients Treated with Ataxia Telangiectasia and Rad3-related Inhibitor Camonsertib in another window
Includes: Supplementary data
Journal Articles

SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression

Available to Purchase
Chuandong Geng, Man-Chao Zhang, Ganiraju C. Manyam, Jody V. Vykoukal, Johannes F. Fahrmann, Shan Peng, Cheng Wu, Sanghee Park, Shakuntala Kondraganti, Daoqi Wang, Brian D. Robinson, Massimo Loda, Christopher E. Barbieri, Timothy A. Yap, Paul G. Corn, Samir Hanash, Bradley M. Broom, Patrick G. Pilié, Timothy C. Thompson
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (21): 4464–4478.
https://doi.org/10.1158/1078-0432.CCR-23-1439
Published: 01 November 2023
View articletitled, SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
Open the PDF for SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression in another window
Includes: Supplementary data
Journal Articles

Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers

Open Access
Timothy P. DiPeri, Kurt W. Evans, Maria Gabriela Raso, Ming Zhao, Yasmeen Q. Rizvi, Xiaofeng Zheng, Bailiang Wang, Bryce P. Kirby, Kathleen Kong, Michael Kahle, Timothy A. Yap, Ecaterina E. Dumbrava, Jaffer A. Ajani, Siqing Fu, Khandan Keyomarsi, Funda Meric-Bernstam
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (21): 4385–4398.
https://doi.org/10.1158/1078-0432.CCR-23-0103
Published: 01 November 2023
View articletitled, Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers
Open the PDF for Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers in another window
Includes: Supplementary data
Journal Articles

Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101)

Open Access
Roberto Carmagnani Pestana, Justin T. Moyers, Jason Roszik, Shiraj Sen, David S. Hong, Aung Naing, Cynthia E. Herzog, Siqing Fu, Sarina A. Piha-Paul, Jordi Rodon, Timothy A. Yap, Daniel D. Karp, Apostolia M. Tsimberidou, Shubham Pant, Maria A. Zarzour, Ravin Ratan, Vinod Ravi, Robert S. Benjamin, Alexander J. Lazar, Wei-Lien Wang, Najat Daw, Jonathan B. Gill, Douglas J. Harrison, Valerae O. Lewis, Christina L. Roland, Shreyaskumar R. Patel, J. Andrew Livingston, Neeta Somaiah, Joseph A. Ludwig, Anthony P. Conley, Nelson Hamerschlak, Richard Gorlick, Funda Meric-Bernstam, Vivek Subbiah
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (9): 1708–1718.
https://doi.org/10.1158/1078-0432.CCR-22-3629
Published: 01 May 2023
View articletitled, Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101)
Open the PDF for Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101) in another window
Includes: Supplementary data
Journal Articles

National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)

Open Access
Funda Meric-Bernstam, James M. Ford, Peter J. O'Dwyer, Geoffrey I. Shapiro, Lisa M. McShane, Boris Freidlin, Roisin E. O'Cearbhaill, Suzanne George, Julia Glade-Bender, Gary H. Lyman, James V. Tricoli, David Patton, Stanley R. Hamilton, Robert J. Gray, Douglas S. Hawkins, Bhanumati Ramineni, Keith T. Flaherty, Petros Grivas, Timothy A. Yap, Jordan Berlin, James H. Doroshow, Lyndsay N. Harris, Jeffrey A. Moscow
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (8): 1412–1422.
https://doi.org/10.1158/1078-0432.CCR-22-3334
Published: 14 April 2023
View articletitled, National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)
Open the PDF for National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH) in another window
Includes: Supplementary data
Journal Articles

A Phase 1 First-in-Human Study of FS118, a Tetravalent Bispecific Antibody Targeting LAG-3 and PD-L1 in Patients with Advanced Cancer and PD-L1 Resistance

Free
Timothy A. Yap, Patricia M. LoRusso, Deborah J. Wong, Siwen Hu-Lieskovan, Kyriakos P. Papadopoulos, Josefin-Beate Holz, Urszula Grabowska, Cristian Gradinaru, Kin-Mei Leung, Sylwia Marshall, Claire S. Reader, Roslin Russell, Richard C.A. Sainson, Claire J. Seal, Christopher J. Shepherd, Fiona Germaschewski, Daniel Gliddon, Omer Stern, Lesley Young, Neil Brewis, Louis Kayitalire, Michelle Morrow
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (5): 888–898.
https://doi.org/10.1158/1078-0432.CCR-22-1449
Published: 01 March 2023
View articletitled, A Phase 1 First-in-Human Study of FS118, a Tetravalent Bispecific Antibody Targeting LAG-3 and PD-L1 in Patients with Advanced Cancer and PD-L1 Resistance
Open the PDF for A Phase 1 First-in-Human Study of FS118, a Tetravalent Bispecific Antibody Targeting LAG-3 and PD-L1 in Patients with Advanced Cancer and PD-L1 Resistance in another window
Includes: Supplementary data